Latest News
GHO Capital Acquires X-Chem to Enhance Small Molecule Discovery Services
Wednesday 03 June 2020

UK-based healthcare-focussed investor GHO Capital Partners LLC (Global Healthcare Opportunities) has acquired US-based biotechnology company X-Chem, Inc., providing small molecule discovery services, the company said.

Terms of the transaction were not disclosed.

GHO acquired X-Chem from an affiliate of The Carlyle Group and Hellman and Friedman LLC.

X-Chem will benefit from GHO's expertise, global network and international resources to accelerate growth.

With continued investment and support from GHO, X-Chem will be able to build on its best-in-class technology to better service partners by expanding the service offering and growing internationally.

BlackArch Partners served as exclusive financial advisor to X-Chem. Latham and Watkins LLP provided legal advice to X-Chem.

Ropes and Gray LLP provided legal advice to GHO, Health Advances provided commercial advice, Deloitte LLP provided tax and IT advice, PwC provided financial and accounting advice, Corporate Risk Solutions and Atlantic Global Risk LLC provided insurance advice, and Bridge House Advisors provided ESG advice.

Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London.

From its Waltham, US headquarters and leveraging a proprietary DEL platform with libraries containing over 200bn small molecules, X-Chem provides drug discovery services to biopharma partners. X-Chem has licensed over 70 research programmes, comprising hundreds of novel chemical entities, to companies throughout the US, Europe and Japan.
Date Published: 03/06/2020